Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634170 | 1.00 | GRIA1 (0.41) | GRIA1GRIA2GRIA3GRIA4HTR5A | |
| SCHEMBL550313 | 0.88 | NOTUM (0.44) | HTR5ADRD2BCHEDRD3NOTUM | |
| SCHEMBL29353774 | 0.88 | NOTUM (0.44) | HTR5ADRD2BCHEDRD3NOTUM | |
| SCHEMBL6656292 | 0.82 | BCHE (0.41) | HTR5ABCHEKDM4EMAPTACHE | |
| SCHEMBL30826409 | 0.78 | NUDT1 (0.47) | GRIA1GRIA2GRIA3GRIA4HTR5A | |
| SCHEMBL5757236 | 0.78 | NUDT1 (0.47) | GRIA1GRIA2GRIA3GRIA4HTR5A | |
| SCHEMBL20111965 | 0.77 | NUDT1 (0.39) | GRIA1GRIA2GRIA3GRIA4DRD2 | |
| SCHEMBL25374470 | 0.76 | GRIA1 (0.45) | GRIA1GRIA2GRIA3GRIA4DRD2 | |
| SCHEMBL30542835 | 0.76 | GRIA1 (0.45) | GRIA1GRIA2GRIA3GRIA4DRD2 | |
| SCHEMBL17969115 | 0.76 | GRIA1 (0.41) | GRIA1GRIA2GRIA3GRIA4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843379-A | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2019-06-04 | — | — | CN | claimed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-11910706-B2 | Light-emitting device including heterocyclic compound and electronic apparatus including the light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-02-20 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-113725387-A | Light-emitting device including heterocyclic compound and electronic apparatus including light-emitting device | 三星显示有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210367156-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-11-25 | — | — | US | disclosed |
| US-20210367156-A1 | LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-11-25 | — | — | US | disclosed |
| US-10889569-B2 | Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-0173208-A1 | Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
| US-4210757-A | Novel naphthoylene-perinones disperse dyestuffs | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4067889-A | 2-CYANO-3-AMINO-BENZANTHRONES AS PRECURSORS | CIBA-GEIGY CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-3970675-A | ANTHRONE-AMIDINE | CIBA-GEIGY CORPORATION (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | GRIA1 2356/4885GRIA2 2947/4885GRIA3 3057/4885 |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | GRIA1 2702/4885GRIA2 3123/4885GRIA3 2745/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | GRIA1 1668/4885GRIA2 2319/4885GRIA3 3469/4885 |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | GRIA1 1222/4885GRIA2 1949/4885GRIA3 1871/4885 |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | GRIA1 2702/4885GRIA2 3123/4885GRIA3 2745/4885 |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | GRIA1 2702/4885GRIA2 3123/4885GRIA3 2745/4885 |
| US-10889569-B2 | Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine | OXTR, CRH, ADCYAP1R1 | GRIA1 785/4885GRIA2 1645/4885GRIA3 1456/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | GRIA1 2202/4885GRIA2 3150/4885GRIA3 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.